top of page

ANAVEX New Website - Untitled Page.png

Search

Targeting M1 Muscarinic & Sigma1 Receptors in Alzheimer's Disease: Reversal of Pathological Hallmark

ANAVEX® Life Sciences Corp.
Mar 29, 2017
1 min read

The 13th International Conference on Alzheimer’s and Parkinson’s Diseases, March 29 to April 2, 2017, in Vienna, Austria.

Hélène Hall, PharmD, PhD

View Presentation

Recent Posts

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

bottom of page